With ten million persons afflicted each year, no one is entirely immune to cancer and its devastating effects on individuals and families. But recent advances in the development of cancer vaccines—either as therapeutic agents or as preventative measures—are hopeful indicators of progress in this field. This volume comprises invited chapters from world-renowned researchers and clinicians that shed light on recent steps forward in immunotherapeutic and preventive approaches for future cancer vaccines.NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.
Author(s): Ralph M. Steinman, Kenichiro Hasumi, Olivera J. Finn, Jacques Banchereau
Edition: 1
Publisher: Wiley-Blackwell
Year: 2009
Language: English
Pages: 122
Scientific and Organizational Challenges in Cancer Immunology (p 1-5)......Page p1
Human Cancer Antigen Mesothelin Is More Efficiently Presented to Mouse Immune System when Targeted to the DEC-205/CD205 Receptor on Dendritic Cells (p 6-17)......Page p6
Brain Tumor Immunotherapy with Type-1 Polarizing Strategies (p 18-23)......Page p18
Harnessing Human Dendritic Cell Subsets to Design Novel Vaccines (p 24-32)......Page p24
Dendritic Cell-Based Vaccines for Pancreatic Cancer and Melanoma (p 33-40)......Page p33
Combining Conventional Therapies with Intratumoral Injection of Autologous Dendritic Cells and Activated T Cells to Treat Patients with Advanced Cancers (p 41-50)......Page p41
Witch Hunt against Tumor Cells Enhanced by Dendritic Cells (p 51-60)......Page p51
Harnessing CD1d-Restricted T Cells toward Antitumor Immunity in Humans (p 61-67)......Page p61
Immunity against Cyclin B1 Tumor Antigen Delays Development of Spontaneous Cyclin B1-Positive Tumors in p53^−/− Mice (p 68-73)......Page p68
Targets of Protective Tumor Immunity (p 74-80)......Page p74
Ident. of Immunologic Biomarkers Assoc. with Clinical Response after Immune-Based Therapy for Cancer (p 81-87)......Page p81
Harnessing Dendritic Cells to Generate Cancer Vaccines (p 88-98)......Page p88
Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells (p 99-106)......Page p99
Strategies to Enhance Therapeutic Activity of Cancer Vaccines: Melanoma as a Model (p 107-117)......Page p107
Hematopoietic Stem and Progenitor Cells and the Inflammatory Response (p 118-121)......Page p118
